https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-01-30 / Vaccines (Basel) 2018 Jan;6(1)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-01-30 / Vaccines (Basel) 2018 Jan;6(1)2018-01-30 00:00:002019-02-15 08:45:23Radiation and Anti-Cancer Vaccines: A Winning Combination
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-01-29 / Oncoimmunology 2018;7(4):e1412901
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-01-29 / Oncoimmunology 2018;7(4):e14129012018-01-29 00:00:002019-02-15 08:47:40Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8 T cell activation in the presence of adjuvant temozolomide
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-01-26 / J Clin Oncol 36, 2018 (suppl 5S; abstr 96)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-01-26 / J Clin Oncol 36, 2018 (suppl 5S; abstr 96)2018-01-26 11:47:012021-05-19 14:28:45Autologous tumor lysate-pulsed dendritic cell vaccination therapy after resection of stage IIA (T2N0, T3N0) esophageal cancer: An analysis of immunological responses.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-01-25 / J Clin Oncol 36, 2018 (suppl 5S; abstr TPS201)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-01-25 / J Clin Oncol 36, 2018 (suppl 5S; abstr TPS201)2018-01-25 11:36:152019-07-17 11:37:00A prospective, randomized, blinded, placebo-controlled, phase IIb trial of an autologous tumor lysate + yeast cell wall particles (YCWP) + dendritic cells (DC) vaccine vs unloaded YCWP + DC and embedded phase I/IIa trial with tumor lysate particle only (TLPO) vaccine in stage III and stage IV (resected) melanoma to prevent recurrence.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-01-21 / Int J Hyperthermia 2018 11;34(7):953-960
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-01-21 / Int J Hyperthermia 2018 11;34(7):953-9602018-01-21 00:00:002019-03-27 11:15:48The effect of modulated electro-hyperthermia on temperature and blood flow in human cervical carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-01-11 / J. Cell. Biochem. 2018 04;119(4):3763-3774
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-01-11 / J. Cell. Biochem. 2018 04;119(4):3763-37742018-01-11 00:00:002019-02-15 08:39:30Hyperthermia enhances radiosensitivity of colorectal cancer cells through ROS inducing autophagic cell death
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-01-10 / Oncotarget 2018 Feb;9(11):10110-10117
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-01-10 / Oncotarget 2018 Feb;9(11):10110-101172018-01-10 00:00:002018-01-10 00:00:00A phase-1/2 study of adenovirus-p53 transduced dendritic cell vaccine in combination with indoximod in metastatic solid tumors and invasive breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-01-09 / Cancer Sci. 2018 Feb;109(2):279-288
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-01-09 / Cancer Sci. 2018 Feb;109(2):279-2882018-01-09 00:00:002019-02-15 09:23:17Newcastle disease virus co-expressing interleukin 7 and interleukin 15 modified tumor cells as a vaccine for cancer immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-01-03 / PLoS ONE 2018;13(1):e0190638
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-01-03 / PLoS ONE 2018;13(1):e01906382018-01-03 00:00:002020-01-08 10:08:47EpCAM peptide-primed dendritic cell vaccination confers significant anti-tumor immunity in hepatocellular carcinoma cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-01-03 / Sci Transl Med 2018 01;10(422)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-01-03 / Sci Transl Med 2018 01;10(422)2018-01-03 00:00:002018-01-03 00:00:00Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade
